After more than 30 years of accumulation, monoclonal antibody drugs have become well-deserved mainstream branches in the field of medicine from targets development to technologies improvement. From clinical research to commercialization strategies,Read More…
Evaluate Pharma, a well-known market research organization in the field of medicine, recently released the report “EP Vantage 2018 Preview”, in which it reviewed the new drug approval in 2017, and predictedRead More…
There is no doubt that this year marks the beginning of CAR-T therapy owing to the advent of two CAR-T therapies and the changes that these therapies have brought to the lives ofRead More…
A new study recently calculated the development costs of 10 new anti-tumor drugs over the 10-year period between 2006 and 2015, and found that the median development time for these 10Read More…
“Brentuximab Vedotin (Antibody-drug conjugate, ADC)was approved by the FDA in 2011 as the first new therapeutic option for patients with Hodgkin lymphoma in more than 30 years. Currently, brentuximab vedotin and nivolumabRead More…
“The global biosimilar market is growing rapidly as patents on blockbuster biologic drugs expire.Although many companies are keen on getting a share in the biosimilars market given its promising outlook, bringing theseRead More…
Actemra/RoActemra® is the first FDA approved drug for treatment of serious or fatal cytokine release syndrome (CRS) caused by CAR-T therapy; CAR-T cell therapy is an immunotherapy used to treat certain typesRead More…
6. AstraZeneca AstraZeneca’s research and development line was mixed last year. The Clinical Phase III trial result of Olaparib used for the treatment of BRCA mutations related advanced ovarian cancer afterRead More…
On August 24th, a reporter was informed from Prof. Guangmei Yan research group at Zhongshan University that this group of researchers identified and gained oncolytic virus M1 synergist with accurate treatment ofRead More…
Generally, when the business of a pharmaceutical giant reaches a plateau, its business volume won’t change much during this period. Instead, it will try to optimize its structure, including R&D and productionRead More…